Investor Relations
Financial calendar
- 14/11/24
Interim report, Q3 2024
- 06/02/25
Year-end report, Q4 2024
- 01/05/25
2024 Annual Report
Latest press releases
Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ)
Today, on 21 October 2024, ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") has held an Extraordinary General Meeting 2024 (the "EGM"). Notice of the EGM and complete proposals for resolutions taken are available on the Company's investor website, https://investor.expres2ionbio.com.
Read moreExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialisation of novel malaria vaccines
Hørsholm, Denmark, 16 October 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, announces that a term sheet has been entered with Serum Institute of India Private Limited (“SIIPL”), the world’s largest vaccine manufacturer. Upon execution of…
Read moreNotice to attend the Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)
N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), reg. no. 559033-3729 (the "Company"), are hereby given notice to attend the Extraordinary General Meeting to be held on 21…
Read moreLatest presentations
BioStock Life Science
- From Seed To Success
16 September 2024
Presentation of
half-year results
15 August 2024
2024
Rights Issue Webinar
14 June 2024